Valeant Bull Case ($70?) Is Now All About The Next CEO
On Wednesday morning's PreMarket Prep, Rand Strategic Partners’ Todd Sullivan discussed how traders should approach the controversial Valeant Pharmaceuticals Intl Inc (NYSE: VRX). Shares are down 83.5 percent in the past year, but investors are divided on whether or not the stock will eventually go to zero or whether the sell-off has created an incredible buying opportunity.
Sullivan told Benzinga the fate of Valeant rests in the hands of the company’s next CEO.
“If they come up with a great CEO, I think the stock could be a screaming buy simply because it is a healthy, functioning company. Yes, there’s a ton of negative press around it, and a rockstar CEO could help handle a lot of that.”
Although the market seems concerned about Valeant’s debt load and the potential for default, Sullivan believes the stock is trading at a very compelling valuation.
“Fundamentally speaking, there’s no reason for the stock to be down at this level. If you just look at valuation based on whatever metric you want to look at –EBITDA, earnings, sales, whatever- it’s trading at a fraction of what its peers are trading at.”
It terms of timing a buy, Sullivan says he’s on the sidelines until a CEO announcement is made and will willingly pay a slightly higher price if the company comes through with a strong leader.
“With a good CEO, this thing could go from $27 to $70 over the next couple of years,” he concluded.
Disclosure: the author holds no position in the stocks mentioned.
Latest Ratings for VRX
|Sep 2016||Deutsche Bank||Initiates Coverage on||Hold|
|Aug 2016||Morgan Stanley||Upgrades||Equal-Weight||Overweight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.